Home Therapeutics Pain

Pain

Latest
Nexium (esomeprazole)
Pain

Grünenthal Acquires Partial Rights to Nexium, Vimovo from AstraZeneca for Up-to-$922M

Molecule structure drawn on board
Pain

Lilly, Dicerna Launch $3.7B+ RNAi Collaboration

Insys Therapeutics says it will ponder its next steps following FDA rejection of its new drug application (NDA) for Buvaya (buprenorphine sublingual spray) as a treatment for moderate-to-severe acute pain.
Pain

Insys Weighs Next Steps after FDA Rejects NDA for Acute Pain...

Pain

Aquinox Axes Half its Workforce after Phase III Failure of Lead...

Teva Pharmaceutical Industries is halting a Phase III trial of fremanezumab (TEV-48125) for chronic cluster headaches
Pain

Teva Halts Phase III Trial of Fremanezumab in Chronic Cluster Headaches

Reports detail a decade of investment trends
Pain

BIO 2018: Depression, Pain Drug Developers Starve for Dollars as Cancer...

Source: NIH
Pain

Opioid Drugs Rush In Where Natural Opioids Fail to Activate

Pain

PixarBio CEO, Two Associates Face Federal Fraud Charges

Hairy skin of a mouse
Pain

Neuropathic Pain Eased by Novel Light-Based Technique

Pain

Genentech, Kineta to Partner on Non-Opioid Pain Treatments

Load more

Recently Featured

Stay Connected

557,187FansLike
46,430FollowersFollow
Copyright © 2019 Genetic Engineering & Biotechnology News. All Rights Reserved.
Scroll Up